{"organizations": [], "uuid": "e8d681e8183d9b045669db5fe687f6bbef4184c6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-flex-pharma-reports-positive-topli/brief-flex-pharma-reports-positive-topline-data-from-exploratory-phase-2-trial-of-flx-787-in-multiple-sclerosis-idUSASC09TKC", "country": "US", "domain_rank": 408, "title": "Flex Pharma Reports Positive Topline Data From Exploratory Phase 2 Trial Of FLX-787 In Multiple Sclerosis", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.039, "site_type": "news", "published": "2018-03-26T19:20:00.000+03:00", "replies_count": 0, "uuid": "e8d681e8183d9b045669db5fe687f6bbef4184c6"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-flex-pharma-reports-positive-topli/brief-flex-pharma-reports-positive-topline-data-from-exploratory-phase-2-trial-of-flx-787-in-multiple-sclerosis-idUSASC09TKC", "ord_in_thread": 0, "title": "Flex Pharma Reports Positive Topline Data From Exploratory Phase 2 Trial Of FLX-787 In Multiple Sclerosis", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "flex pharma reports positive topline data from exploratory phase", "sentiment": "negative"}, {"name": "multiple sclerosis  flex pharma inc", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 20 AM / Updated 21 minutes ago BRIEF-Flex Pharma Reports Positive Topline Data From Exploratory Phase 2 Trial Of FLX-787 In Multiple Sclerosis Reuters Staff 1 Min Read   Flex Pharma Inc: * FLEX PHARMA REPORTS POSITIVE TOPLINE DATA FROM EXPLORATORY PHASE 2 TRIAL OF FLX-787 IN MULTIPLE SCLEROSIS * FLEX PHARMA - FLX-787 REDUCED CRAMP/SPASM FREQUENCY AND INCREASED CRAMP-FREE DAYS IN MS PATIENTS IN PRE-SPECIFIED ANALYSIS OF PARALLEL TREATMENT PHASE * FLEX PHARMA INC - FLX-787 WAS GENERALLY WELL TOLERATED WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS REPORTED Source text for Eikon: Further company coverage:", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-26T19:20:00.000+03:00", "crawled": "2018-03-26T14:30:49.020+03:00", "highlightTitle": ""}